Yu, Ming-Chin

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 469

PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Tzeng, S.-F., Yu, Y.-R., Park, J., von Renesse, J., Hsiao, H.-W., Hsu, C.-H., Garnica, J., Chen, J., Chiu, L.-T., Santol, J., et al. (2025) · Cancer Discovery

Cancer Immunotherapy and BiomarkersCancer, Lipids, and Metabolism

Cited by 49